Search
Hydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigationalHydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928.
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsSynonyms: N-Hydroxyurea, N-CarbamoylhydroxylamineVortioxetine
go.drugbank.com/drugs/DB09068ApprovedInvestigationalreceptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. … More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: KELAC® 20 MG, BRINTELLIX® 20 MGGrade 2 Astrocytoma
go.drugbank.com/conditions/DBCOND0168502Drugs: VorasidenibSynonyms: Grade 2 AstrocytomaFenyramidol
go.drugbank.com/drugs/DB13414InvestigationalCategories: Heterocyclic Compounds, 1-RingProducts: CABRAL 800 MG/3 ML IM ENJEKSİYONLUK ÇÖZELTİ (3 AMPUL), PHEBDOL 800 MG/3 ML IM ENJEKSİYONLUK ÇÖZELTİ, 3 ADETSelenious acid
go.drugbank.com/drugs/DB11127ApprovedSelenious acid is the acid form of sodium selenite, a form of selenium [L1910]. Selenium is an essential trace element and antioxidant. It is a cofactor metabolic enzyme regulation. … One study showed efficacy in the prevention of malignancy while utilizing a selenium supplement in humans.
Mixtures: TRACUTIL® 10 ML AMPOLLAS, Tricare Prenatal 2-part Daily Prenatal Vitamin SystemProducts: Selenase 100 Mikrogramm/2 ml - Lösung zum Einnehmen, Selepen Inj 40mcg/ml USPCenobamate
go.drugbank.com/drugs/DB06119ApprovedInvestigational[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABA<sub>A</sub> and inhibits voltage gated sodium channels. … [L10653] Cenobamate was granted FDA approval on 21 November 2019.[L10653]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersProducts: XCOPRI TITRATION PACK 12.5 mg, 25 mg, XCOPRI TITRATION PACK 50 mg, 100 mgLurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalFood and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
Categories: Heterocyclic Compounds, 2-Ring, Adrenergic alpha-2 Receptor AntagonistsProducts: ESLUX® 40 MG TABLETAS RECUBIERTAS, LATUDA® 40 MG TABLETAS RECUBIERTASAbrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigationalAbrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). … [L39774] The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of autoimmune and inflammatory diseases,
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsProducts: CIBINQO® 50 MG, CIBINQO® 200 MGPazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalPazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: VOTRIENT® 200 MG, VOTRIENT® 400 MGAtazanavir
go.drugbank.com/drugs/DB01072ApprovedInvestigationalFood and Drug Administration (FDA) approved atazanavir on June 20, 2003.
Mixtures: ANCEF ® R, ANCEF ® RCategories: P-glycoprotein inducers, P-glycoprotein inhibitors